A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Part of paid clinical trials in Oceanside, California.

Sponsor
argenx
Study ID
NCT06284954
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Dermatomyositis
  • Myositis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empasiprubart IV — BIOLOGICAL
    Intravenous infusion with Empasiprubart IV
  • Placebo IV — OTHER
    Intravenous infusion with Placebo IV

Study Details

This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).

Key Dates

Start date
Aug 20, 2024
Status verified
Sep 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
3 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empasiprubart
    Patients receiving Empasiprubart IV
  • Placebo Comparator: Placebo
    Patients receiving Placebo IV

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: Up to 90 weeks ]

Locations (9)

Find similar trials in Oceanside, CA

Related Studies